The median five-year survival rate for patients diagnosed with PDAC is just three to five percent.
“We are excited to be able to work with the leading cancer research and care institution in the world to develop therapies for patients with this devastating cancer,” Clive Wood, senior corporate vice president of Discovery Research at Boehringer Ingelheim, said. “This partnership is a perfect match because it combines MD Anderson’s outstanding capabilities in pre-clinical concept validation and clinical testing with Boehringer Ingelheim’s strength in developing innovative medicines in novel target spaces.”
The research conducted by the two agencies will be aimed at developing therapeutic methods and identifying PDAC biomarkers to select patients who could benefit from new therapies.
“At MD Anderson, we have created integrated platforms that will enable the discovery of more effective therapeutics for cancer patients,” Timothy Heffernan, executive director and co-leader of MD Anderson’s Center for Co-Clinical Trials, said. “This alliance combines expertise in cancer genetics and translational medicine with outstanding drug discovery and development, and it has great potential to conquer devastating diseases like pancreatic cancer.”
Boehringer Ingelheim is one of the world’s top 20 pharmaceutical companies. It is based in Ingelheim, Germany. For more information, visit www.boehringer-ingelheim.com.
Boehringer Ingelheim was founded in 1885 by Albert Boehringer in Ingelheim am Rhein.